Insights
43 results found with the tag "Pharmaceuticals & Life Sciences"
- Articles
ABPI and UK Government bring forward VPAG pricing review
01 May 2025The UK Government and the Association of the British Pharmaceutical Industry (ABPI) have agreed to accelerate the planned review of the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG).- Articles
Sustainability - why this is now crucial for pharma business leaders?
01 Apr 2025Whether your business is in early stage drug discovery and R&D or manufacturing, supply, and distribution, every part of the pharma ecosystem is now under increasing pressure to adopt sustainable practices.- Articles
Spending on medicines and medical devices increases but VPAG clawback reach record levels
01 Apr 2025NHS spending on medicines, appliances and medical devices in England hit £19.9bn in 2023/24, with £14.6bn in branded medicine sales. However, the VPAG clawback is meanwhile expected to be an unprecedented £3.5bn in 2025, £1bn more than previously forecast- Articles
NHS England abolished - what does this mean for pharma?
01 Apr 2025This is not about abolishing the NHS, but a plan to redirect money from bureaucracy to frontline treatments of patients.- Articles
What remedy is left for contract breach after Court gives wide exclusion of liability for anticipated profits?
03 Mar 2025Parties to commercial contracts often include exclusion clauses to manage their liability risks. This may contain a list of items such as lost profits, lost revenue, and lost savings among other items.
- Articles
Sustainability trends: key issues shaping the future of Pharmaceuticals and Life Sciences
03 Mar 2025Leaders in net zero certification, Planet Mark, have recently identified the key sustainability trends for businesses in the UK and beyond. What do these trends mean for the Pharmaceuticals and Life Sciences sector?
